CCR5 as a treatment target in pulmonary arterial hypertension.
about
Endogenous Sulfur Dioxide: A New Member of Gasotransmitter Family in the Cardiovascular SystemMaraviroc: a review of its use in HIV infection and beyondComputational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and pro-angiogenic therapeutics.The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes.Bone Marrow-derived Cells Contribute to the Pathogenesis of Pulmonary Arterial Hypertension.Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancer-associated fibroblast accumulation.HIV-associated pulmonary arterial hypertension: from bedside to the future.Novel Targets of Drug Treatment for Pulmonary Hypertension.Maintaining lung health with longstanding HIV.Pharmacological treatment of HIV-associated pulmonary hypertension.Non-infectious pulmonary disorders in HIV.Extracellular Calpain/Calpastatin Balance Is Involved in the Progression of Pulmonary Hypertension.Off-label use of maraviroc in clinical practice.The HIV co-receptor CCR5 regulates osteoclast function.Emerging Therapeutics in Pulmonary Hypertension.A Time- and Compartment-Specific Activation of Lung Macrophages in Hypoxic Pulmonary Hypertension.Dynamic and Diverse Changes in the Functional Properties of Vascular Smooth Muscle Cells in Pulmonary Hypertension.Roles for the CX3CL1/CX3CR1 and CCL2/CCR2 Chemokine Systems in Hypoxic Pulmonary Hypertension.Macrophage Regulation during Vascular Remodeling: Implications for Pulmonary Hypertension Therapy.Macrophage Immunomodulation: The Gatekeeper for Mesenchymal Stem Cell Derived-Exosomes in Pulmonary Arterial Hypertension?
P2860
Q26770047-45DB5690-D481-4982-B82B-960A987168DBQ26778504-938521BD-49B6-49F0-9EB4-84D245A2B616Q30278668-14DFF8AC-EEAC-4885-B763-ADC10A5F2716Q35115789-9E49705C-FB3E-4E57-8B78-09D45844CA34Q36847595-3EEC251D-D10F-45E2-A5BD-3C361FBDD219Q37565466-04EBBC1B-8C57-4134-9CE0-BE0C85E97404Q38365222-B5054F99-3A4A-42FF-9C66-225328BA94AAQ38504399-80BA9926-069D-45AA-8885-48650CA0E89DQ38629654-AC5030FB-440D-4978-A9B4-CD9F5B2714EFQ38728500-FFC3000E-2C9F-4F44-92D3-1B236A0CFC5EQ39106214-750CA77A-B2E9-4E30-8D4D-40A28F3E687DQ40855297-1AA2F77C-BAB5-49AB-AAFF-58C323B52A34Q42654565-81691ED0-B46B-43E2-8E81-C75D41A88E50Q47126167-8D94F0FC-9C67-48DF-A8C8-F47EEE9D1903Q47700134-B33950E1-C3D6-4BA9-B478-D2080DB3E916Q48150398-F10FDD4F-6A9A-4E0C-BA57-E81A2C5B1BD0Q49552882-2F25E148-1B77-4FEA-8A09-B0DB6DA08D84Q51167771-A4CCC221-1F1A-441D-B478-F10D1E5BDD07Q52874552-DD2BFB9D-09B3-47F7-99B4-C4AE96E6D9FAQ58700113-B180533F-606D-44BD-A913-D1358D163C91
P2860
CCR5 as a treatment target in pulmonary arterial hypertension.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
CCR5 as a treatment target in pulmonary arterial hypertension.
@en
CCR5 as a treatment target in pulmonary arterial hypertension.
@nl
type
label
CCR5 as a treatment target in pulmonary arterial hypertension.
@en
CCR5 as a treatment target in pulmonary arterial hypertension.
@nl
prefLabel
CCR5 as a treatment target in pulmonary arterial hypertension.
@en
CCR5 as a treatment target in pulmonary arterial hypertension.
@nl
P2093
P2860
P50
P1433
P1476
CCR5 as a treatment target in pulmonary arterial hypertension.
@en
P2093
Amal Houssaini
Aurélien Parpaleix
Christophe Combadière
Elisabeth Marcos
Karen A Norris
Lucie Poupel
Marion Delcroix
Mirna Saker
Nathalie Mouraret
Rozenn Quarck
P2860
P304
P356
10.1161/CIRCULATIONAHA.114.010757
P407
P577
2014-07-03T00:00:00Z